Results 341 to 350 of about 256,425 (387)
Some of the next articles are maybe not open access.
Personalised antiplatelet therapies for coronary artery disease: what the future holds.
European Heart Journal, 2023Coronary artery disease (CAD) is one of the leading causes of death globally, and antiplatelet therapy is crucial for both its prevention and treatment.
D. Capodanno, D. Angiolillo
semanticscholar +1 more source
European Journal of Clinical Investigation, 1994
Abstract.The evidence in support of the safety and efficacy of aspirin in the secondary prevention of platelet dependent vascular occlusion is compelling. The utility of this drug has stalled the development of potential competitors, such as thromboxane antagonists.
G A, Fitzgerald, E A, Meagher
openaire +2 more sources
Abstract.The evidence in support of the safety and efficacy of aspirin in the secondary prevention of platelet dependent vascular occlusion is compelling. The utility of this drug has stalled the development of potential competitors, such as thromboxane antagonists.
G A, Fitzgerald, E A, Meagher
openaire +2 more sources
European Heart Journal, 2021
AIMS The role of antiplatelet therapy in patients with spontaneous coronary artery dissection (SCAD) undergoing initial conservative management is still a matter of debate, with theoretical arguments in favour and against its use.
E. Cerrato +28 more
semanticscholar +1 more source
AIMS The role of antiplatelet therapy in patients with spontaneous coronary artery dissection (SCAD) undergoing initial conservative management is still a matter of debate, with theoretical arguments in favour and against its use.
E. Cerrato +28 more
semanticscholar +1 more source
Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review.
Journal of the American Medical Association (JAMA), 2021Importance Acute coronary syndrome (ACS) is a major cause of morbidity and mortality in the United States with an annual incidence of approximately 1 million.
Hassan Kamran +6 more
semanticscholar +1 more source
Medical Journal of Australia, 1999
Antiplatelet drugs protect against myocardial infarction, stroke, cardiovascular death and other serious vascular events in patients with a history of previous vascular events or known risk factors for cardiovascular disease. Aspirin reduces the risk of serious vascular events in patients at high risk of such an event by about a quarter and is ...
R I, Baker, G J, Hankey
openaire +3 more sources
Antiplatelet drugs protect against myocardial infarction, stroke, cardiovascular death and other serious vascular events in patients with a history of previous vascular events or known risk factors for cardiovascular disease. Aspirin reduces the risk of serious vascular events in patients at high risk of such an event by about a quarter and is ...
R I, Baker, G J, Hankey
openaire +3 more sources
Clinical pharmacology of antiplatelet drugs
Expert Review of Clinical Pharmacology, 2022Introduction Platelets play a key role in arterial thrombosis and antiplatelet therapy is pivotal in the treatment of cardiovascular disease. Current antiplatelet drugs target different pathways of platelet activation and show specific pharmacodynamic ...
Georg Gelbenegger, B. Jilma
semanticscholar +1 more source
Hematology, 2009
Abstract The introduction of aspirin as an anti-thrombotic agent some 50 years ago has changed the therapeutic approach in cardiovascular medicine. Since platelets play a key role in the development of arterial thrombosis, antiplatelet drugs serve as a cornerstone in the prevention and the treatment of these conditions.
David, Varon, Galia, Spectre
openaire +2 more sources
Abstract The introduction of aspirin as an anti-thrombotic agent some 50 years ago has changed the therapeutic approach in cardiovascular medicine. Since platelets play a key role in the development of arterial thrombosis, antiplatelet drugs serve as a cornerstone in the prevention and the treatment of these conditions.
David, Varon, Galia, Spectre
openaire +2 more sources
The American Journal of Medicine, 1996
The major clinical indication for antiplatelet therapy has been the prevention of arterial thrombosis. Arterial thrombi are composed of predominantly platelets formed under conditions of elevated shear stress at sites of atherosclerotic vascular injury and disturbed blood flow.
openaire +2 more sources
The major clinical indication for antiplatelet therapy has been the prevention of arterial thrombosis. Arterial thrombi are composed of predominantly platelets formed under conditions of elevated shear stress at sites of atherosclerotic vascular injury and disturbed blood flow.
openaire +2 more sources
Australian and New Zealand Journal of Medicine, 1998
AbstractAspirin is an established therapy for the management of acute myocardial infarction (AMI) and unstable angina. Secondary prevention with chronic aspirin therapy is also indicated for patients with stable angina.Aspirin inhibits cyclo‐oxygenase‐I, a key enzyme in the biosynthetic pathway leading to the production of thromboxane A2.
H D, White, J K, French, C J, Ellis
openaire +2 more sources
AbstractAspirin is an established therapy for the management of acute myocardial infarction (AMI) and unstable angina. Secondary prevention with chronic aspirin therapy is also indicated for patients with stable angina.Aspirin inhibits cyclo‐oxygenase‐I, a key enzyme in the biosynthetic pathway leading to the production of thromboxane A2.
H D, White, J K, French, C J, Ellis
openaire +2 more sources
Hospital Medicine, 2000
Within the last few years antiplatelet therapy has developed exponentially, with new agents being tested in an increasing number of clinical scenarios. The mechanism of action of these newer agents and evidence of benefit is prevented in this review.
openaire +2 more sources
Within the last few years antiplatelet therapy has developed exponentially, with new agents being tested in an increasing number of clinical scenarios. The mechanism of action of these newer agents and evidence of benefit is prevented in this review.
openaire +2 more sources